Avelox

Basic Avelox information

• INN (international nonproprietary name): moxifloxacin
• Brand names available in the United Kingdom: Avelox 400 mg film-coated tablets
• ATC code: J01MA14
• Forms and strengths: film-coated tablet 400 mg (oral); IV solution/flexibag 400 mg/250 mL (0.8% NaCl) for intravenous infusion
• Manufacturers in the United Kingdom: Bayer
• Registration status in the United Kingdom: approved by the MHRA; prescription only (Rx)
• OTC / Rx classification: prescription only (Rx)

Legal status and availability in the UK

Avelox (moxifloxacin 400 mg) is a prescription-only medicine (POM) in the UK.

In our online pharmacy, Avelox is available without a prescription, with discreet delivery to the United Kingdom in 9–21 days.

Clinical effectiveness in the UK

Are clinicians using Avelox in real NHS practice, and when is it effective?

Moxifloxacin (Avelox 400 mg) is an effective option for specific and often more severe infections within NHS pathways.

It is used for community-acquired pneumonia, acute bacterial sinusitis and acute exacerbations of chronic bronchitis when first-line agents are unsuitable or resistance is suspected.

Intravenous moxifloxacin in a 400 mg/250 mL flexibag supports hospital step-down strategies by enabling earlier oral switch due to high oral bioavailability.

Antimicrobial stewardship in the NHS prioritises narrower-spectrum agents where possible, meaning routine primary-care prescribing of moxifloxacin is limited.

Prescribing is typically restricted when beta-lactams are ineffective, when resistance is likely, or when oral compliance and IV→oral switching benefits outweigh risks.

Tolerance is variable, with some patients reporting gastrointestinal or CNS side effects that can affect continuation.

Typical uses in NHS practice:

• Community-acquired pneumonia where first-line agents are unsuitable.
• Complicated intra-abdominal and selected skin infections requiring IV therapy.
• Cases with suspected or confirmed beta-lactam resistance where moxifloxacin’s spectrum is appropriate.

Indications and expanded uses

What conditions is Avelox licensed for, and when might it be used off-label?

MHRA-approved indications for moxifloxacin (Avelox 400 mg tablets and IV) cover several adult infections.

Approved adult indications and typical regimens from the product information are:

• Community-acquired pneumonia — 400 mg once daily for 7–14 days.
• Acute bacterial sinusitis — 400 mg once daily for 7–10 days.
• Acute bacterial exacerbation of chronic bronchitis — 400 mg once daily for 5 days.
• Complicated skin/skin-structure infections — 400 mg once daily for 7–21 days, often IV then oral.
• Complicated intra-abdominal infections — 400 mg once daily for 5–14 days.
• Pelvic inflammatory disease — 400 mg once daily for 14 days.

Moxifloxacin is not recommended for use in children or adolescents under 18 years because of musculoskeletal risk.

Off-label use is limited and generally reserved for multidrug-resistant infections or when alternatives are unsuitable for oral step-down therapy.

Composition and brand landscape

What exactly is inside an Avelox tablet, and how is it supplied in the UK?

The active ingredient is moxifloxacin (INN), 400 mg per film-coated tablet.

The intravenous formulation is 400 mg/250 mL in a 0.8% NaCl flexibag for infusion.

ATC code J01MA14 classifies moxifloxacin as a systemic fluoroquinolone antibacterial.

In the United Kingdom the common trade name is Avelox, the originator product from Bayer AG, and the product is supplied as 400 mg film-coated tablets.

Generic moxifloxacin is also available in oral and IV presentations; tablets are supplied in blister packs and the IV form in flexibags for hospitals.

Contraindications and special precautions

Who should not take Avelox, and what checks should a pharmacist make?

Absolute contraindications include hypersensitivity to moxifloxacin or other quinolones, a history of quinolone-related tendon disorders and a history of myasthenia gravis.

Relative cautions apply where the risk of adverse events is higher.

These include known prolonged QT interval, concurrent QT-prolonging medicines, uncorrected hypokalaemia, severe bradycardia or heart failure, and use with systemic corticosteroids which increases tendon rupture risk.

Pregnancy and breastfeeding: moxifloxacin must not be used.

Moxifloxacin is not recommended for children or adolescents under 18 years.

Advise patients about lifestyle restrictions such as avoiding driving or operating machinery if they experience dizziness or visual disturbance.

Pharmacists should perform medication reconciliation to detect QT‑prolonging co-prescriptions and encourage Yellow Card reporting for suspected reactions.

• Absolute contraindications: Hypersensitivity to moxifloxacin/quinolones; prior quinolone-related tendon disorder; myasthenia gravis.
• Caution scenarios: Prolonged QT, electrolyte disturbances, severe cardiac disease, systemic steroids, elderly with cardiovascular comorbidity.
• Lifestyle restrictions: Avoid strenuous exercise if tendon pain develops; moderate alcohol; avoid driving if affected by CNS symptoms.

Dosage guidelines

How should Avelox be dosed and what are duration expectations for common conditions?

The standard adult dose is 400 mg once daily, taken orally or given intravenously as 400 mg/250 mL infusion.

Typical durations from the product information are:

• Community-acquired pneumonia: 7–14 days.
• Acute bacterial sinusitis: 7–10 days.
• Acute exacerbation of chronic bronchitis: 5 days.
• Complicated skin/skin-structure infections: 7–21 days (often IV→oral).
• Complicated intra-abdominal infections: 5–14 days.
• Pelvic inflammatory disease: 14 days.

No dose adjustment is required for renal impairment; moxifloxacin should not be used in severe hepatic impairment, and paediatric use is contraindicated.

Missed dose advice is to take the tablet as soon as remembered unless the next dose is due soon; do not double up.

In the event of overdose, seek emergency care and monitor ECG because of QT prolongation risk.

In NHS practice, pharmacists and prescribers document indication and expected duration on labels and electronic prescriptions to support adherence and stewardship.

Interactions overview

Which medicines and products should be avoided or timed carefully with Avelox?

Moxifloxacin may prolong the QT interval, so avoid co-prescribing with other QT-prolonging agents such as certain antiarrhythmics, some SSRIs, antipsychotics and macrolides where possible.

Concurrent systemic corticosteroids increase the risk of tendon disorders.

Drugs that can cause hypokalaemia, for example some diuretics, can heighten the risk of arrhythmia when combined with moxifloxacin.

Antacids and products containing multivalent cations such as iron, zinc or sucralfate can reduce absorption and should be separated from dosing by several hours if possible.

Moxifloxacin may be taken with or without food, but patients should be warned that alcohol can worsen CNS effects.

Electronic prescribing systems and pharmacy checks should flag high-risk combinations and prompt a medicines review.

• High‑risk classes to avoid: Antiarrhythmics, macrolide antibiotics, certain antipsychotics and SSRIs with QT risk.
• Timing advice: Separate antacids/iron/zinc/sucralfate by several hours from moxifloxacin dosing.

Comparable medicines and preferences

How does Avelox compare with other antibiotics and when is it preferred?

NHS prescribing generally favours narrower-spectrum agents such as amoxicillin, doxycycline or macrolides when appropriate.

Within the fluoroquinolone group, levofloxacin and ciprofloxacin are alternatives, with levofloxacin commonly compared for community-acquired pneumonia.

Choice between moxifloxacin and alternatives depends on spectrum of activity, QT and tendon risk, local antimicrobial resistance patterns, renal function and comorbidities.

Pros of moxifloxacin include once-daily dosing and strong IV/oral switch availability with broad respiratory and intra-abdominal activity.

Cons include safety warnings about tendon injury, peripheral neuropathy and QT prolongation, plus tighter stewardship restrictions and regulatory scrutiny.

Frequently asked questions

Q: Can I drive while taking Avelox?

A: If you experience dizziness, visual disturbance or other CNS effects, avoid driving or operating machinery until you have fully recovered.

Q: Is Avelox safe in pregnancy or for children?

A: Not recommended for children or adolescents under 18 years due to musculoskeletal risks.

A: It must not be used during pregnancy or breastfeeding; discuss alternatives with your prescriber.

Q: What side effects should prompt urgent review?

A: Sudden tendon pain or swelling, numbness or signs of peripheral neuropathy, palpitations or syncope suggesting arrhythmia, and severe skin reactions — stop the medicine and seek urgent care.

Q: Can I stop early when I feel better?

A: Complete the prescribed course unless advised otherwise by your clinician to reduce development of resistance.

Guidelines for proper use (pharmacist counselling and NHS advice)

What should a pharmacist tell every patient being supplied Avelox in the community?

Confirm the indication and duration are printed on the NHS label and match the prescription.

Advise the patient to take the 400 mg tablet whole with a full glass of water, with or without food.

Explain the need to separate antacids, iron and other multivalent cation products by several hours from dosing.

Warn about tendon pain, peripheral neuropathy and signs of QT effects and instruct patients to stop the medicine and seek help if such symptoms occur.

Discuss driving and alcohol cautions if dizziness or other CNS effects are reported.

For hospital-to-community transitions, ensure IV→oral plans are documented on discharge prescriptions and patient portals.

Stewardship steps include reserving moxifloxacin for guideline-specified indications, recording the prescribing rationale in the patient record and reporting suspected adverse reactions to the MHRA Yellow Card scheme.

• Counselling script: Confirm dose and duration; advise on administration and interaction timing; list red-flag symptoms.
• Red‑flag signs: Tendon pain, numbness, palpitations, severe rash — stop and seek urgent care.
• Stewardship documentation: Record indication, duration and rationale in the medical record; report adverse events to Yellow Card.

Delivery across the United Kingdom